Literature DB >> 10719175

Interaction of taxol with human serum albumin.

M Purcell1, J F Neault, H A Tajmir-Riahi.   

Abstract

Taxol (paclitaxel) is an anticancer drug, which interacts with microtuble proteins, in a manner that catalyzes their formation from tubulin and stabilizes the resulting structures (Nogales et al., Nature 375 (1995) 424-427). This study was designed to examine the interaction of taxol with human serum albumin (HSA) in aqueous solution at physiological pH with drug concentrations of 0.0001-0.1 mM, and HSA (fatty acid free) concentration of 2% w/v. Gel electrophoresis, absorption spectra and Fourier transform infrared (FTIR) spectroscopy with self-deconvolution and second-derivative resolution enhancement were used to determine the drug binding mode, binding constant and the protein secondary structure in the presence of taxol in aqueous solution. Spectroscopic evidence showed that taxol-protein interaction results into two types of drug-HSA complexes with overall binding constant of K=1.43 x 10(4) M(-1). The molar ratios of complexes were of taxol/HSA 30/1 (30 mM taxol) and 90/1 (90 mM taxol) with the complex ratios of 1.9 and 3.4 drug molecules per HSA molecule, respectively. The taxol binding results in major protein secondary structural changes from that of the alpha-helix 55 to 45% and beta-sheet 22 to 26%, beta-anti 12 to 15% and turn 11 to 16%, in the taxol-HSA complexes. The observed spectral changes indicate a partial unfolding of the protein structure, in the presence of taxol in aqueous solution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719175     DOI: 10.1016/s0167-4838(99)00251-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin-bound paclitaxel-derived albumin from human serum.

Authors:  Takamichi Sato; Manami Okazaki; Junko Sano; Chihiro Kato; Kazuhisa Shimizu; Masayuki Kitagawa
Journal:  Biomed Rep       Date:  2021-02-11

2.  Study on the interaction of an anthracycline disaccharide with DNA by spectroscopic techniques and molecular modeling.

Authors:  Yan Lu; Gong-Ke Wang; Juan Lv; Gui-Sheng Zhang; Qing-Feng Liu
Journal:  J Fluoresc       Date:  2010-10-16       Impact factor: 2.217

3.  Lymph node effective vascular permeability and chemotherapy uptake.

Authors:  Eelco F J Meijer; Cedric Blatter; Ivy X Chen; Echoe Bouta; Dennis Jones; Ethel R Pereira; Keehoon Jung; Benjamin J Vakoc; James W Baish; Timothy P Padera
Journal:  Microcirculation       Date:  2017-08       Impact factor: 2.628

4.  Reversible exposure of hydrophobic residues on albumin as a novel strategy for formulation of nanodelivery vehicles for taxanes.

Authors:  A G Garro; D M Beltramo; R V Alasino; V Leonhard; V Heredia; I D Bianco
Journal:  Int J Nanomedicine       Date:  2011-06-13

5.  Determination of LMF binding site on a HSA-PPIX complex in the presence of human holo transferrin from the viewpoint of drug loading on proteins.

Authors:  Zohreh Sattar; Mohammad Reza Saberi; Jamshidkhan Chamani
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

6.  A biophysical study on the mechanism of interactions of DOX or PTX with α-lactalbumin as a delivery carrier.

Authors:  Behdad Delavari; Fatemeh Mamashli; Bahareh Bigdeli; Atefeh Poursoleiman; Leila Karami; Zahra Zolmajd-Haghighi; Atiyeh Ghasemi; Samaneh Samaei-Daryan; Morteza Hosseini; Thomas Haertlé; Vladimir I Muronetz; Øyvind Halskau; Ali Akbar Moosavi-Movahedi; Bahram Goliaei; Ali Hossein Rezayan; Ali Akbar Saboury
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

7.  Binding Performance of Human Intravenous Immunoglobulin and 20(S)-7-Ethylcamptothecin.

Authors:  Yong-Chun Liu; Ying-Ying Li; Xiao-Jun Yao; Hui-Li Qi; Xiao-Xia Wei; Jian-Ning Liu
Journal:  Molecules       Date:  2018-09-18       Impact factor: 4.411

8.  Synthesis and In Vitro Antiproliferative Activity of 11-Substituted Neocryptolepines with a Branched ω-Aminoalkylamino Chain.

Authors:  Elkhabiry Shaban; Marta Świtalska; Li Wang; Ning Wang; Fan Xiu; Ikuya Hayashi; Tran Anh Ngoc; Sachie Nagae; Samah El-Ghlban; Shiho Shimoda; Ahmed Abdel Aleem El Gokha; Ibrahim El Tantawy El Sayed; Joanna Wietrzyk; Tsutomu Inokuchi
Journal:  Molecules       Date:  2017-11-12       Impact factor: 4.411

Review 9.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20

10.  Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?

Authors:  Iole Cucinotto; Lucia Fiorillo; Simona Gualtieri; Mariamena Arbitrio; Domenico Ciliberto; Nicoletta Staropoli; Anna Grimaldi; Amalia Luce; Pierfrancesco Tassone; Michele Caraglia; Pierosandro Tagliaferri
Journal:  J Drug Deliv       Date:  2013-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.